# Unichem Laboratories (NSE: UNICHEMLAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/UNICHEMLAB · Pivot · prices to 22 Oct 2026

Unichem Laboratories (NSE: UNICHEMLAB) closed at ₹495.95 on 22 Oct 2026, down 3.51% on the day. With a market capitalisation of ₹3,492 Cr, it ranks 917th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 13.8× trailing earnings, against a return on equity of 9.3% in FY26. Over the past year the share price has risen 5.5%. Its 52-week range is ₹278.20 (30 Mar 2026) to ₹687.20 (9 Jul 2026); the last close is 27.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹575 Cr (−2.1% year on year) and net profit ₹11 Cr (−79.4%), on a consolidated basis. Promoters held 70.22% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹495.95 |
| Market cap | ₹3,492 Cr |
| P/E (trailing) | 13.8 |
| ROE | 9.3% (FY26) |
| ROCE | 4.3% (FY26) |
| Debt to equity | 0.17 |
| 52-week high | ₹687.20 (9 Jul 2026) |
| 52-week low | ₹278.20 (30 Mar 2026) |
| 1-year return | +5.5% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹575 Cr | −2.1% | ₹11 Cr | −79.4% | ₹1.55 |
| Q3 FY26 | ₹521 Cr | −2.2% | ₹264 Cr | +356.9% | ₹37.54 |
| Q2 FY26 | ₹579 Cr | +25.3% | −₹12 Cr | −139.0% | −₹1.69 |
| Q1 FY26 | ₹527 Cr | +18.0% | −₹10 Cr | −213.1% | −₹1.49 |
| Q4 FY25 | ₹587 Cr | +36.0% | ₹53 Cr | — | ₹7.52 |
| Q3 FY25 | ₹533 Cr | +22.7% | ₹58 Cr | −31.1% | ₹8.22 |
| Q2 FY25 | ₹462 Cr | +11.2% | ₹30 Cr | — | ₹4.34 |
| Q1 FY25 | ₹446 Cr | +5.5% | ₹9 Cr | — | ₹1.31 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹2,111 Cr | ₹138 Cr |
| FY24 | ₹1,705 Cr | −₹70 Cr |
| FY23 | ₹1,343 Cr | −₹164 Cr |
| FY22 | ₹1,270 Cr | ₹34 Cr |
| FY21 | ₹1,235 Cr | ₹35 Cr |
| FY20 | ₹1,104 Cr | −₹61 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 70.22%
- Foreign institutions: 0.90%
- Domestic institutions: 10.46%
- Non-institutions: 18.42%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Gufic Biosciences](https://app.pivotnow.in/stock/GUFICBIO) | ₹401.55 | ₹4,027 Cr | 62.7 | — |
| [Gujarat Themis Biosyn](https://app.pivotnow.in/stock/GUJTHEM) | ₹365.70 | ₹3,985 Cr | 85.4 | — |
| [Aarti Drugs](https://app.pivotnow.in/stock/AARTIDRUGS) | ₹381.15 | ₹3,479 Cr | 17.9 | — |
| [Solara Active Pharma Sciences](https://app.pivotnow.in/stock/SOLARA) | ₹650.75 | ₹3,140 Cr | — | — |
| [Ind-Swift Laboratories](https://app.pivotnow.in/stock/INDSWFTLAB) | ₹347.05 | ₹3,018 Cr | 71.6 | — |
| [Advanced Enzyme Technologies](https://app.pivotnow.in/stock/ADVENZYMES) | ₹265.45 | ₹2,972 Cr | 17.6 | — |

## Questions and answers

### What is the share price of Unichem Laboratories today?

Unichem Laboratories (NSE: UNICHEMLAB) last closed at ₹495.95 on 22 Oct 2026. Its 52-week high is ₹687.20 and its 52-week low is ₹278.20.

### What is the market cap of Unichem Laboratories?

Unichem Laboratories' market capitalisation is ₹3,492 Cr (₹3,492 Cr) at the 22 Oct 2026 close, ranking 917th among the NSE companies Pivot tracks.

### What is the P/E ratio of Unichem Laboratories?

Unichem Laboratories trades at a trailing P/E of 13.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 62.7.

### What is the ROE and ROCE of Unichem Laboratories?

Return on equity was 9.3% in FY26 and return on capital employed was 4.3% in FY26 (consolidated figures).

### Is Unichem Laboratories a debt-free company?

No. Unichem Laboratories' debt-to-equity ratio was 0.17 in FY26, with total debt of ₹39 Cr.

### What were Unichem Laboratories' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Unichem Laboratories reported revenue of ₹575 Cr, −2.1% year on year, and net profit of ₹11 Cr, −79.4% year on year.

### How has Unichem Laboratories stock performed over the last year?

Unichem Laboratories' share price has risen 5.5% over the past year, −6.3% over three months and −9.4% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Unichem Laboratories?

As of 30 Jun 2026: promoters 70.22%, foreign institutions 0.90%, domestic institutions 10.46%, non-institutions 18.42%.

### Who are Unichem Laboratories' competitors?

The listed Pharma & Healthcare companies closest to Unichem Laboratories by market cap are Gufic Biosciences, Gujarat Themis Biosyn, Aarti Drugs, Solara Active Pharma Sciences, Ind-Swift Laboratories and Advanced Enzyme Technologies.

### Is Unichem Laboratories a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Unichem Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on UNICHEMLAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.